Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Change in Account Payables (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Change in Account Payables for 10 consecutive years, with $10.4 million as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 335.21% to $10.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.1 million through Dec 2025, up 325.95% year-over-year, with the annual reading at $3.1 million for FY2025, 325.95% up from the prior year.
  • Change in Account Payables for Q4 2025 was $10.4 million at Akebia Therapeutics, up from -$8.8 million in the prior quarter.
  • The five-year high for Change in Account Payables was $18.9 million in Q4 2022, with the low at -$13.8 million in Q3 2021.
  • Average Change in Account Payables over 5 years is -$688000.0, with a median of -$1.8 million recorded in 2022.
  • The sharpest move saw Change in Account Payables plummeted 272.51% in 2021, then skyrocketed 491.65% in 2022.
  • Over 5 years, Change in Account Payables stood at $3.2 million in 2021, then surged by 491.65% to $18.9 million in 2022, then tumbled by 76.2% to $4.5 million in 2023, then crashed by 46.84% to $2.4 million in 2024, then soared by 335.21% to $10.4 million in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at $10.4 million, -$8.8 million, and $3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.